Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I just had a chance to review yesterday's trading. Over 60,000 shares were bought between 2:00 and 3:30 PM. Not insignificant...Someone wanted to add to, or gather a position. Too long without a significant announcement. Overdue on announcements relating to financing, lab successes, research coverage, partnerships, etc. Could see one last drop to the 60 cent area before a sustained move upward. My bet: We will be North of $1.00 in 30-60 days...FWIW...
grrdvm,
I believe that when CYGX starts moving, it will take our collective breaths away...Yes, 60 cents is rediculous for this stock...
GRRDVM, There are a number of biotechs out there, with far less prospects and excitement, that are trading higher than CYGX. I believe it is only a matter of time, and I believe weeks to a month or so, before we see CYGX trading over $1.00. There are too many possibilities here to allow this stock to wallow below $1.00. One significant announcement and we should head to the low to mid $1.00 range. JMO.
Thanks CHIPPED, You are first response to my comments. Wondered why no comments...We need funding to relieve fears...We need to gain a following with good research and press...Wondering where JM Dutton Research disappeared to. They had put out some cogent research in the past. The analyst there seemed to have a great grasp of the science. She had recommended the stock at 25 cents, before it headed over $1.00. Anyone who has not read her report should go to www.jmdutton.com and read it. We can only hope for a follow-up... I am long this stock for over a year, and will add more with a funding announcement...Off to the Colorado ski slopes at the break of dawn...
MAD,
Check out SAMM on the pinks. Only about 13 million shares outstanding. Dredging in politically favorable environment in Guiana. Just received financing. Will have five dredges operating shortly. Two operating now. Profitable...
The risk here is that the company miscalculates on their ability to get there stock higher before the possibility of an exogenous factor negatively impacts liquidity in the market, and money flows to the biotech sector. The ole "bird in the hand" concept usually proves to be the right option. Stating you have cash on hand for three or so months does not leave one with a cozy feeling...I believe managemnt must seek out and capture at least two years worth of capital to put these types of concerns to rest. Market reaction would be quite favorable, despite the dilution. We are talking about huge revenues if our products reach commercialization. There would be no excuse if management missed the current opportunity in this favorable capital raising environment...I have to assume the company has some major announcements anticipated over the next 30-60 days. As I said before, if this company was still private, I would bet an investment banker would sign on to begin the process of taking this company public at between $5 and $10 per share. Certainly there must be interest in funding this company at current PPS levels.
Agree with you...Where is the grant announcement? It should have coincided with the shareholder meeting...
Great insight... I think the wild card here is the efforts in India. This will provide the shorter term excitement, as will the funding which, if it comes from sophisticated investors, will validate the company's game plan. I believe we will see at least a $2.00 stock by mid year. Too many good things going on here...
Skooby,
Just a sniff about a funding or partnership, or success in the trials, and this will see a gap-up bigger than a solar flare.
Arnold,
Top tier bankers are in the elite group of firms like Goldman Sachs, Merrill Lynch, Lehman Brothers, Citigroup, etc. It is unlikely you would get any of these to take on CYGX at this stage. However, there is a second tier of quite reputable firms that would have an interest. These firms would be your target for funding.
Texas, Great synopsis and insight. Skooby you are right on all counts. I feel much better about where the company is heading. This company is, as I originally expected, an undiscovered gem...After a two year investment, I believe we are at the point where very big things are about to unfold. This will be a huge year for the company.
All that said, the company must focus on securing funds for the long term. As I said previously, there is much money out there for biotechs with good stories. If this company was private, it could easily find an investment banker to begin readying an IPO to be priced in the $5 - $10 range.
Let me be clear on my view...I truly believe we have something momentus here...This should be, and I expect it will be, a spectacular year for all of us. However, management must step up to the plate and put this company on firm financial footing now...Biotechs have not been in such a favorable light for years. We must compete for the capital that is now available. Management must be proactive, and should tell us what the game plan is...Having the best kept secret does not cut it...
The Board of Directors are the keepers of the gate...They are ultimately responsible for decisions of management. Mr. OCampo has put his reputation on the line with this company. Let's hope he is providing the necessary and correct advice. I do not know the CFO, except for his short biography in company documents. The current business climate, with all the scandals that have surfaced over the past year, underscores the importance of both a good, strong Board, and a CFO of stature and skill. Let's hope we have both...
Is it conceivable that no company or banker has stepped forward to invest in this company? Are we wrong in our assessment that CYGX has breakthrough products in development?Management should outline for its shareholders what steps it has taken to secure meaningful funding. In light of the precarious financial plight of the company, we should expect that the company was in talks with various parties regarding funding. They were quick to raise capital when the stock was in the low penny range. Were we not in the same financial plight when the stock was hovering at one dollar? Was funding sought when the stock was in the 90's or over a dollar? The company will not gain recognition until there is validation of their efforts. That will ony come when a respectable company or banker steps up and raises significant funds for CYGX. NOW IS THE TIME... The money flow spigots are open to biotechs. If we are truly cutting edge, we should be a magnet for funds. Does the company have management capable enough to accomplish the obvious and necessary?
Skooby,
If you are referring to me, I am no basher. I have owned a sizeable position for almost two years. At that time I figured it would take about 2 years to see this company get traction. While it has, the environment for raising money has greatly improved. My chagrin has been not seeing the company secure itself in this more receptive environment. There is money to be garnered. Even IPO'shave come to market, with a backlog building. I would bet that CYGX, if it were private today, could find a banker to begin the process of taking it public, probably at s target price between 5 and 10 dollars per share. Mr. Skolnik should review his strategy, as well as his staff, to ensure that he has the right talent to capitalize on their successes to date. It is not business as usual anymore. No more excuses about needing to do deals in the pennies per share. The big guys are looking for small companies with pipelines. HELLO! Here we are. Proaction please!
Focusing on managemnt, and its decisions, are key to any discussion about the success of a company. Someone mentioned the role and credentials of the CFO. When you have a scientist at the helm of a company, you must look to the strength of the CFO to lead the business side, especially the finance and funding side. The question here is, does the CFO provide the right guidance for the President on funding matters. We should be brought up to date on how proactive he has been in bringing money into the company. Being a relatively undiscovered company, a well thought out plan to attract capital should have been planned and executed. As shareholders, and owners of the company, management should lay out that plan for us. It would be interesting to hear if the company has been approached by another biotech or large investor. The annual meeting would be the perfect time for management to address this. I live in Colorado, and will try to attend the meeting next week if my schedule permits. For those attending, let's make sure the question is asked...
Arnold,
The company must complete a significant capital raise to secure its future. The technology looks very promising, but investors will shy away until a partnership with a big-pharma is secured, or until operating cash to carry them to clinicals is in the bank...
Arnold, Remember, issuing additional shares represents dilution..."Authorizing" additional shares does not, unless they are issued...
Arnold,
The increased authorization would not lower the value of existing shares, unless they were issued. Even if they were issued, probably in pieces as needed, you would think that management would be issuing them and, in return, getting an asset of some kind for that issuance. The asset could be cash from their sale, for example.
It is quite baffling that a company with such prospects is unable to secure a meaningful capital raise. The lack, thereof, is unsettling. Is current management capable of formulating and securing a sizeable funding? They certainly know how to give stock away in the single digits. How about a raise at current market levels? Let's put the company on firm footing for a couple of years. Where's Ocampo in this process? There is a great deal of money out there for the right company and products. The IPO pipeline is filling up in the biotech arena. CYGX will be competing with these companies for capital. Great prospects here, but management must start thinking outside the box...
As I said...Get ready for a push before the shareholders meeting. Always good to go into those meetings with happy campers present...
Get Ready for the move prior to the Annual Meeting.EOM
It is quite obvious that this stock wants to go higher. The market makers let the stock move up quickly on a sizeable buy order. Because they do not have stock, they must be shorting to the buyer, and then bring the stock back down when the buying is through, in hopes of covering there. I believe this stock will easily be over $1.00 at the time of the annual meeting.
If you like gold, check out SAMM. In operation for over 5 years. Just received funding, with more to come shortly. In a prolific and politically stable country in South America. Should have at least five dredges up shortly. About profitable with only two running now. And, the best point of all, only about 10 million shares outstanding.
With some of you estimating that a commercial product will not be out for years and years, let's not forget the very real possibility that approval of a CYGX product will occur in Asia or Europe well before the U.S. The markets there are significantly bigger than the U.S. market. How about India alone, or China...Those approval processes should pick up steam this year with, in my estimation, a commercial product in 12-18 months. In the interim, we should be getting many interesting announcements from the company, relating to everything from trial results and new patents, to funding and joint ventures. These announcements should garner new interest in the stock, and gradually move the PPS higher, until a blockbuster announcement blows the lid off. In my opinion, there is no other bio-tech company that has CYGX's upside potential.
Skooby,
Look forward to sitting at the front table with you! By the way, Dutton Research as been quite silent for some time. I would hope and suspect we will be getting some follow-up from them shortly. They have done a great job, with solid research.
Skooby,
Very good...You are brilliant...What did you say, by the way: 3-5 dollars by the end of THIS year! Your credibility is below sea level.
With the company's cash quite scarce, as noted in their recent filings, it would be nice if the company could at least say they are exploring a number of avenues for financing, and are hopeful of a positive resolution. It seems they missed an opportunity to do a financing at the $1.00 level; alot better than the 10 cents and below level they recently received. Management on the ball???
By the way, FYI, I am long with, I am sure, multiples of your ownership. I believe strongly in this company, but wish it would share their financing plans.
Hogger,
Sorry...You had an audience with two senior execs, and that's all you could get? Where's their financing? Have they been approached, or have they reached out for financing? Don't forget the shareholders own the company...Management should be forthcoming on this important issue.